{"groups":[{"description":"Participants received matching placebo to venetoclax orally once a day (QD) plus cytarabine 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.\n\nParticipants continued treatment until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation were met.","id":"FG000","title":"Placebo + Low Dose Cytarabine (LDAC)"},{"description":"Participants received venetoclax 600 mg orally once a day plus cytarabine 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.\n\nParticipants continued treatment until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation were met.","id":"FG001","title":"Venetoclax + Low Dose Cytarabine (LDAC)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"40"}],"type":"Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"68"},{"groupId":"FG001","numSubjects":"143"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"68"},{"groupId":"FG001","numSubjects":"142"}],"type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"103"}],"comment":"As of 15 August 2019","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"40"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants with acute myeloid leukemia (AML) were randomized to one of two treatment arms in a 1:2 ratio (placebo + low-dose cytarabine \\[LDAC\\] or venetoclax + LDAC). Randomization was stratified by AML status (secondary, de novo), age (18 - \\< 75, ≥ 75) and region (United States \\[US\\], European Union \\[EU\\], China, Japan, rest of world).","recruitmentDetails":"Participants were enrolled at 76 sites globally. The study is currently ongoing; the results reported below include the primary analysis for efficacy which was conducted after 133 deaths occurred (data cut-off date of 15 February 2019), and an unplanned 6-month follow-up update for overall survival and safety (15 August 2019 cut-off date)."}